US OptionsDetailed Quotes

IMMP250117P2500

Watchlist
  • 0.45
  • 0.000.00%
15min DelayClose Jan 7 16:00 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

News

Comments

    我要向钱看
    我要向钱看
    Jan 5 17:47
    UPDATES
    $Immutep (IMMP.US)$ Immutep (ASX:IMM) said the phase 1 INSIGHT-003 trial reached an enrollment target of about 50 patients across Germany, according to a Monday Australian bourse filing.
    INSIGHT-003 is an investigator-initiated study led by the Frankfurt Institute of Clinical Cancer Research IKF evaluating a triple combination therapy in first-line non-small cell lung cancer patients.
    It is testing eftilagimod alpha in combination with antiPD-1 therapy, pembrolizumab, and doublet chemoth...
    我要向钱看
    我要向钱看
    Dec 17, 2024 07:40
    UPDATES
    $Immutep (IMMP.US)$ Immutep Reports Initial Safety Data For IMP761, The First LAG-3 Agonist, In Phase I Trial With No Treatment-Related Adverse Events; Additional Data Expected In H1 2025 To Support Autoimmune Disease Treatment Potential
    Jaguar8
    Jaguar8
    Dec 16, 2024 07:09
    NEWS
    $Immutep (IMMP.US)$
    Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II
    Monday, 16th December at 8:00 am
    • Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for development of blocking LAG-3 therapeutics, including Immutep's anti-LAG-3 small molecule program
    • Data also supports eftilagimod alfa's (efti) preferential binding to a subset of MHC Class II molecules on anti...
    我要向钱看
    我要向钱看
    Dec 16, 2024 02:24
    UPDATES
    $Immutep (IMMP.US)$ Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II
    Jaguar8
    Jaguar8
    Dec 12, 2024 07:18
    NEWS
    $Immutep (IMMP.US)$
    Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024
    Immutep (NASDAQ: IMMP) has announced promising clinical results from Cohort B of the TACTI-003 Phase IIb trial, evaluating eftilagimod alpha (efti) combined with KEYTRUDA® in head and neck cancer patients. The study shows significant improvements in patients with PD-L1 CPS <1 expression, including:
    - Median overall survival (OS) not yet reached with 67% 12-month OS rate
    - Progression-fr...
Read more